RCS - Graft Polymer (UK) - Non Regulatory Appnt of Senior Scientific Advisor

Solvonis Therapeutics

30/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240730:nRSd2899Ya&default-theme=true

RNS Number : 2899Y  Graft Polymer (UK) PLC  30 July 2024

RNS Reach - non-regulatory announcement

 

30 July 2024

 

Graft Polymer (UK) plc (LON: GPL)

Appointment of Senior Scientific Adviser

Professor David Nutt - renowned leader in neuroscience and public health

 

Graft Polymer (UK) plc ("Graft Polymer" or the "Company"), an innovative drug
delivery systems development company, is pleased to announce the appointment
of Professor David Nutt as the Company's Senior Scientific Adviser, effective
immediately.

 

This appointment follows the announcement, on 18 July 2024, of Graft Polymer's
collaboration agreement with Awakn Life Sciences Corp (CSE:AWKN OTCQB:AWKNF)
("Awakn").

 

Professor Nutt, a preeminent authority in neuropsychopharmacology, is a
Professor at Imperial College London and Chief Research Officer at Awakn. He
is renowned for his leadership role in development of UK drug policy research,
having chaired the UK Advisory Council on the Misuse of Drugs, and led
numerous influential studies on the effects of drugs on the brain and public
health.  Professor Nutt has made significant contributions to the UK's
understanding and treatment of mental health disorders and addiction. His work
has been instrumental in shaping evidence-based policies and treatment
protocols, earning him recognition as one of the most influential voices in UK
neuroscience and public health.

 

In consideration for becoming the Company's Senior Scientific Adviser
Professor Nutt has been granted 10,000,000 nominal cost options (with an
exercise price of £0.001) over the Company's ordinary shares under the
Company's Long Term Incentive Plan (the "LTIP"). These options will have a
term of three years from the date of grant and will vest in three equal parts:
one third immediately, one third on the first anniversary, and the final third
on the second anniversary of Professor Nutt's appointment. Following this
grant, the Company has a total of 10,000,000 outstanding options, equivalent
to 0.4% of the Company's current issued share capital.

 

Commenting on the appointment, Anthony Tennyson, CEO of Graft Polymer, said:

"We are honoured to welcome Professor Nutt as our Senior Scientific Adviser.
His unparalleled expertise and leadership in UK research will be a tremendous
asset to our team and his work aligns perfectly with our mission to innovate
in drug delivery solutions."

 

Professor Nutt commented:

"I am excited to be working with Graft Polymer as its Senior Scientific
Adviser and to help to contribute to their innovative approaches to drug
delivery. These approaches present a unique opportunity to advance the
treatment of complex conditions, particularly in the US, the UK, and key
international markets."

 

 

Enquiries:

Graft Polymer (UK) Plc

Anthony Tennyson, CEO and Executive Director. Email:
anthonytennyson@graftpolymer.co.uk

Yifat Steuer, CFO and Executive Director, Email: yifat@graftpolymer.co.uk

 

Allenby Capital (Broker)

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

+44 (0) 20 3328 5656

 

 

About Professor David Nutt

Prof. David Nutt is currently the Edmond J. Safra Professor of
Neuropsychopharmacology and Director of the Neuropsychopharmacology Unit in
the Division of Brain Sciences at Imperial College, London and also Chief
Research Officer at Awakn Life Sciences Corp.

 

After 11+ entry to Bristol Grammar School David was awarded an Open
Scholarship to Downing College Cambridge and then completed his medical
training at Guy's Hospital London, continuing in neurology to MRCP. After
completing his psychiatric training in Oxford, he continued there as a
lecturer and then later as a Wellcome Senior Fellow in psychiatry. He then
spent two years as Chief of the Section of Clinical Science in the National
Institute of Alcohol Abuse and Alcoholism in NIH, Bethesda, USA. On returning
to England in 1988 he set up the Psychopharmacology Unit in Bristol
University, an interdisciplinary research grouping spanning the departments of
Psychiatry and Pharmacology before moving to Imperial College London in
December 2008 where he leads a similar group with a particular focus on brain
imaging especially PET.

 

David was previously President of the European Brain Council, the European
College of Neuropsychopharmacology (ECNP), the British Neuroscience
Association (BNA) and the British Association of Psychopharmacology (BAP). He
is a Fellow of the Royal Colleges of Physicians and of Psychiatrists and of
the Academy of Medical Sciences. He is also the UK Director of the European
Certificate and Masters in Affective Disorders Courses and a member of the
International Centre for Science in Drug Policy. He has edited the Journal of
Psychopharmacology for over two decades and acts as the psychiatry drugs
advisor to the British National Formulary. He has published over 500 original
research papers, a similar number of reviews and books chapters, eight
government reports on drugs and 33 books.

 

Previously he has been a member and then Chair of the Advisory Committee on
the Misuse of Drugs (ACMD - 1998-2009), a member of the HEFCE/NHS Senior
Lecturer Selection Panel and of the MRC Neuroscience Board. Other previous
national contributions include serving as the medical expert on the
Independent Inquiry into the Misuse of Drugs Act (2000 Runciman report), and
membership of the Committee on Safety of Medicines, the Committee on NHS drugs
and the Ministry of Defence Science Advisory Board. He was the clinical
scientific lead on the 2004/5 UK Government Foresight initiative "Brain
science, addiction and drugs" that provided a 25-year vision for this area of
science and public policy.

 

David broadcasts widely to the general public both on radio and television
including BBC science and public affairs programmes on therapeutic as well as
illicit drugs, their harms and their classification. He also lectures widely
to the public as well as to the scientific and medical communities; for
instance has presented three times at the Cheltenham Science Festival and
several times for Café Scientifiques. In 2010 The Times Eureka science
magazine included him in the 100 most important figures in British Science.

 

About Graft Polymer (UK) Plc

Graft Polymer plc ("Graft Polymer") (LON: GPL) is an innovative biopolymer
drug delivery systems development company dedicated to enabling
biopharmaceutical companies to enhance the effectiveness of their
therapeutics. Our proprietary platform, a bioabsorbable self-nanoemulsifying
drug delivery system (SNEDDS), represents a cutting-edge solution in drug
delivery technology. By integrating active pharmaceutical ingredients (APIs)
into our novel, patented delivery systems, we enable clients to improve the
pharmacokinetics, bioavailability, and stability of their therapeutics.

 

For more information, please visit www.graftpolymer.co.uk

 

 

About Reach announcements 

This is a RNS Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies to
distribute media only / non-regulatory news releases into the public
domain.  Information required to be notified under the AIM Rules for
Companies, Market Abuse Regulation or other regulation would be disseminated
as an RNS regulatory announcement and not on Reach. 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFZGZNLLRGDZM